Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, filed for an initial public offering (IPO) to raise $150 million.

Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Swiss-based AstraZeneca. The deal appears consistent with Ramaswamy’s business model – acquire cast-off compounds from big pharmaceutical companies at bargain-bin prices and convince investors to invest in developing them.

Medical device maker Teleflex Inc. said on Tuesday it would buy privately held NeoTract Inc. to strengthen its portfolio of urology devices in its second billion-dollar deal in the past nine months.

U.S. medical equipment supplier Becton Dickinson and Co. will acquire C. R. Bard Inc. in a $24 billion cash-and-stock deal, adding Bard’s devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said.

Aytu BioScience announced the execution of a long-term, exclusive license agreement for the U.S. commercial rights to Natesto (testosterone) Nasal Gel.

Canadian company Concordia Healthcare[2] (CXR.TO[3]), headquartered in Oakville, Ontario, announced[4] today that it is buying Amdipharm Mercury Limited[5] (AMCo) from Cinven[6] for $3.5 billion. Cinven is a European private equity firm. The deal will be a combination of cash, common shares of Concordia, and a performance-based earn-out payable in cash. “This acquisition is a key […]